RU2004123623A - Системы осмотической доставки - Google Patents
Системы осмотической доставки Download PDFInfo
- Publication number
- RU2004123623A RU2004123623A RU2004123623/15A RU2004123623A RU2004123623A RU 2004123623 A RU2004123623 A RU 2004123623A RU 2004123623/15 A RU2004123623/15 A RU 2004123623/15A RU 2004123623 A RU2004123623 A RU 2004123623A RU 2004123623 A RU2004123623 A RU 2004123623A
- Authority
- RU
- Russia
- Prior art keywords
- osmotic
- tablet according
- specified
- acid
- tablet
- Prior art date
Links
- 230000003204 osmotic effect Effects 0.000 title claims 16
- 239000003826 tablet Substances 0.000 claims 22
- 239000003814 drug Substances 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 6
- 239000002357 osmotic agent Substances 0.000 claims 6
- 230000005070 ripening Effects 0.000 claims 6
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 4
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 4
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000010410 layer Substances 0.000 claims 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 claims 1
- 239000005711 Benzoic acid Substances 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims 1
- 239000001361 adipic acid Substances 0.000 claims 1
- 235000011037 adipic acid Nutrition 0.000 claims 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 229960005070 ascorbic acid Drugs 0.000 claims 1
- 235000010233 benzoic acid Nutrition 0.000 claims 1
- 239000007894 caplet Substances 0.000 claims 1
- 235000015165 citric acid Nutrition 0.000 claims 1
- 239000002389 essential drug Substances 0.000 claims 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims 1
- 239000001530 fumaric acid Substances 0.000 claims 1
- 235000011087 fumaric acid Nutrition 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000001630 malic acid Substances 0.000 claims 1
- 235000011090 malic acid Nutrition 0.000 claims 1
- 239000002356 single layer Substances 0.000 claims 1
- 239000004334 sorbic acid Substances 0.000 claims 1
- 235000010199 sorbic acid Nutrition 0.000 claims 1
- 229940075582 sorbic acid Drugs 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 235000002906 tartaric acid Nutrition 0.000 claims 1
- 239000011975 tartaric acid Substances 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (15)
1. Осмотическая фармацевтическая таблетка, содержащая:
(a) однослойное прессованное ядро, включающее:
(i) не созревающее лекарство, имеющее растворимость на дозу менее около 1 мл-1,
(ii) гидроксиэтилцеллюлозу, имеющую средневесовую молекулярную массу от около 300000 до около 2000000, и
(iii) осмотический агент,
где указанная гидроксиэтилцеллюлоза присутствует в указанном ядре в количестве от около 2,0 до около 20 мас.% и осмотический агент присутствует в количестве от около 15 до около 75 мас.%,
(b) водопроницаемый слой вокруг указанного ядра; и
(c) по меньшей мере, один канал внутри указанного слоя (b) для доставки указанного лекарства в жидкую среду, окружающую указанную таблетку.
2. Осмотическая таблетка по п.1, где указанная гидроксиэтилцеллюлоза имеет средневесовую молекулярную массу от 700000 до 1500000.
3. Осмотическая таблетка по п.2, где указанная гидроксиэтилцеллюлоза присутствует в указанном ядре в количестве от около 3 до около 15 мас.%.
4. Осмотическая таблетка по п.1, где указанный осмотический агент, присутствующий в указанном ядре, является сахаром.
5. Осмотическая таблетка по п.4, где указанный сахар является сорбитом.
6. Осмотическая таблетка по п.1, где комбинация указанного не созревающего лекарства и указанного осмотического агента имеет среднюю пластичность от около 100 до около 200 МПа.
7. Осмотическая таблетка по п.1, где комбинация указанного не созревающего лекарства и указанного осмотического агента имеет среднюю прочность на растяжение от около 0,8 до около 2,0 МПа.
8. Осмотическая таблетка по п.1, где комбинация указанного не созревающего лекарства и указанного осмотического агента имеет средний показатель хрупкого разрушения менее примерно 0,2.
9. Осмотическая таблетка по п.1, которая дополнительно включает агент, модифицирующий рН, присутствующий в указанной таблетке в количестве от около 5 до около 25 мас.%.
10. Осмотическая таблетка по п.9, где указанный агент, модифицирующий рН, используемый в комбинации с не созревающим основным лекарством, выбран из группы, включающей винную кислоту, адипиновую кислоту, аскорбиновую кислоту, бензойную кислоту, лимонную кислоту, фумаровую кислоту, глутаминовую кислоту, яблочную кислоту, сорбиновую кислоту и толуолсульфоновую кислоту.
11. Осмотическая таблетка по п.9, где такая таблетка имеет соотношение площади поверхности к объему больше 0,6 мм-1.
12. Осмотическая таблетка по п.1, где указанная таблетка имеет продолговатую форму, так что соотношение большей оси к меньшей оси составляет от 1,3 до 3.
13. Осмотическая таблетка по п.1, где указанная таблетка имеет форму каплеты, так что соотношение большей оси к меньшей оси составляет от 1,3 до 3.
14. Осмотическая таблетка по п.12 или 13, имеющая также единственное отверстие, полученное в пределах 3 мм от пересечения большей оси и внешнего обода таблетки.
15. Осмотическая таблетка по п.1, где, указанное не созревающее лекарство составляет, по меньшей мере, 30 мас.% указанного ядра таблетки.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35315102P | 2002-02-01 | 2002-02-01 | |
| US60/353,151 | 2002-02-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2004123623A true RU2004123623A (ru) | 2005-04-20 |
Family
ID=27663182
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2004123623/15A RU2004123623A (ru) | 2002-02-01 | 2003-01-28 | Системы осмотической доставки |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20030175346A1 (ru) |
| EP (1) | EP1469826B1 (ru) |
| JP (1) | JP2005518418A (ru) |
| KR (1) | KR20040083492A (ru) |
| CN (1) | CN1625388A (ru) |
| AR (1) | AR038373A1 (ru) |
| AT (1) | ATE345776T1 (ru) |
| BR (1) | BR0307320A (ru) |
| CA (1) | CA2474425A1 (ru) |
| DE (1) | DE60309832T2 (ru) |
| ES (1) | ES2277632T3 (ru) |
| GT (1) | GT200300017A (ru) |
| MX (1) | MXPA04007437A (ru) |
| NO (1) | NO20043646L (ru) |
| NZ (1) | NZ533986A (ru) |
| PA (1) | PA8565201A1 (ru) |
| PE (1) | PE20030801A1 (ru) |
| PL (1) | PL372172A1 (ru) |
| RU (1) | RU2004123623A (ru) |
| TW (1) | TW200302748A (ru) |
| UY (1) | UY27644A1 (ru) |
| WO (1) | WO2003063823A2 (ru) |
| ZA (1) | ZA200405406B (ru) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0203296D0 (en) | 2002-02-12 | 2002-03-27 | Glaxo Group Ltd | Novel composition |
| US8637512B2 (en) | 2002-07-29 | 2014-01-28 | Glaxo Group Limited | Formulations and method of treatment |
| US7829507B2 (en) * | 2003-09-17 | 2010-11-09 | Halliburton Energy Services Inc. | Subterranean treatment fluids comprising a degradable bridging agent and methods of treating subterranean formations |
| WO2006057912A2 (en) * | 2004-11-24 | 2006-06-01 | Teva Pharmaceutical Industries, Ltd. | Rasagiline orally disintegrating compositions |
| GB2421431B (en) * | 2004-12-24 | 2007-10-10 | Aquasol Ltd | Dosing systems |
| WO2006072878A1 (en) * | 2005-01-07 | 2006-07-13 | Ranbaxy Laboratories Limited | Oral dosage forms of sertraline having controlled particle size and processes for their preparation |
| DE102005009240A1 (de) * | 2005-03-01 | 2006-09-07 | Bayer Healthcare Ag | Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften |
| US8637080B2 (en) * | 2007-06-28 | 2014-01-28 | Osmotica Kereskedelmi és Szolgáltató, KFT | Rupturing controlled release device comprising a subcoat |
| CN105581984A (zh) * | 2009-04-09 | 2016-05-18 | 阿尔科米斯制药爱尔兰有限公司 | 药物递送组合物 |
| PT2442791T (pt) | 2009-06-16 | 2020-02-06 | Pfizer | Formas farmacêuticas de apixaban |
| IT1399240B1 (it) * | 2010-03-22 | 2013-04-11 | Trere Chimica S A S | Metodo e prodotto per il trattamento di sostanze alcooliche, mosti d'uva e derivati |
| CN102379858B (zh) * | 2011-10-12 | 2013-06-19 | 中国药科大学 | 一种可装载大剂量难溶性药物并促进其吸收的渗透泵片 |
| JP6041823B2 (ja) | 2013-03-16 | 2016-12-14 | ファイザー・インク | トファシチニブの経口持続放出剤形 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US39691A (en) * | 1863-08-25 | Improvement in pipe-couplings | ||
| US64556A (en) * | 1867-05-07 | Improved belt-punch | ||
| US143272A (en) * | 1873-09-30 | Improvement in saw-sets | ||
| US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) * | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4036228A (en) * | 1975-09-11 | 1977-07-19 | Alza Corporation | Osmotic dispenser with gas generating means |
| US4077407A (en) * | 1975-11-24 | 1978-03-07 | Alza Corporation | Osmotic devices having composite walls |
| US4111202A (en) * | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system for the controlled and delivery of agent over time |
| US4265874A (en) * | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US4327725A (en) * | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
| US4627850A (en) * | 1983-11-02 | 1986-12-09 | Alza Corporation | Osmotic capsule |
| US4610686A (en) * | 1983-11-02 | 1986-09-09 | Alza Corporation | Controlled delivery of haloperidol by an osmotic delivery system |
| US4732915A (en) * | 1983-11-02 | 1988-03-22 | Alza Corporation | Process for increasing solubility of drug |
| US4627971A (en) * | 1985-04-22 | 1986-12-09 | Alza Corporation | Osmotic device with self-sealing passageway |
| CH668187A5 (de) * | 1986-08-07 | 1988-12-15 | Ciba Geigy Ag | Therapeutisches system mit systemischer wirkung. |
| US5108756A (en) * | 1989-01-12 | 1992-04-28 | Pfizer Inc. | Dispensing devices powered by lyotropic liquid crystals |
| US5071607A (en) * | 1990-01-31 | 1991-12-10 | Alza Corporatino | Method and apparatus for forming a hole in a drug dispensing device |
| US5284662A (en) * | 1990-10-01 | 1994-02-08 | Ciba-Geigy Corp. | Oral osmotic system for slightly soluble active agents |
| US5869097A (en) * | 1992-11-02 | 1999-02-09 | Alza Corporation | Method of therapy comprising an osmotic caplet |
| HU213407B (en) * | 1993-12-09 | 1997-06-30 | Egyt Gyogyszervegyeszeti Gyar | Process for producing tablet with diffusive-osmotic release |
| US5698224A (en) * | 1994-06-27 | 1997-12-16 | Alza Corporation | Tacrine therapy |
| US5736159A (en) * | 1995-04-28 | 1998-04-07 | Andrx Pharmaceuticals, Inc. | Controlled release formulation for water insoluble drugs in which a passageway is formed in situ |
| US5654005A (en) * | 1995-06-07 | 1997-08-05 | Andrx Pharmaceuticals, Inc. | Controlled release formulation having a preformed passageway |
| US6361796B1 (en) * | 1996-10-25 | 2002-03-26 | Shire Laboratories, Inc. | Soluble form osmotic dose delivery system |
| AU721653B2 (en) * | 1996-10-25 | 2000-07-13 | Supernus Pharmaceuticals, Inc. | Soluble form osmotic dose delivery system |
| US5837379A (en) * | 1997-01-31 | 1998-11-17 | Andrx Pharmaceuticals, Inc. | Once daily pharmaceutical tablet having a unitary core |
| US6485748B1 (en) * | 1997-12-12 | 2002-11-26 | Andrx Pharmaceuticals, Inc. | Once daily pharmaceutical tablet having a unitary core |
| US6224907B1 (en) * | 1998-03-06 | 2001-05-01 | Alza Corporation | Anti-asthma therapy |
| US6099859A (en) * | 1998-03-20 | 2000-08-08 | Andrx Pharmaceuticals, Inc. | Controlled release oral tablet having a unitary core |
| US6156342A (en) * | 1998-05-26 | 2000-12-05 | Andex Pharmaceuticals, Inc. | Controlled release oral dosage form |
| US20010031279A1 (en) * | 1998-11-02 | 2001-10-18 | Evangeline Cruz | Controlled delivery of antidepressants |
| JP2000171868A (ja) * | 1998-12-08 | 2000-06-23 | Canon Inc | フィルム送り装置、フィルム使用装置および光学機器 |
| US6706283B1 (en) * | 1999-02-10 | 2004-03-16 | Pfizer Inc | Controlled release by extrusion of solid amorphous dispersions of drugs |
| US6352721B1 (en) * | 2000-01-14 | 2002-03-05 | Osmotica Corp. | Combined diffusion/osmotic pumping drug delivery system |
| AR026148A1 (es) * | 2000-01-21 | 2003-01-29 | Osmotica Argentina S A | Dispositivo osmotico con pasaje preformado que aumenta de tamano |
| WO2001091716A1 (en) * | 2000-05-30 | 2001-12-06 | Add Advanced Drug Delivery Technologies Ag | Peroral therapeutic system comprising glipizide |
| IN190699B (ru) * | 2001-02-02 | 2003-08-16 | Sun Pharmaceutical Ind Ltd | |
| US20030185882A1 (en) * | 2001-11-06 | 2003-10-02 | Vergez Juan A. | Pharmaceutical compositions containing oxybutynin |
-
2003
- 2003-01-27 US US10/352,283 patent/US20030175346A1/en not_active Abandoned
- 2003-01-27 TW TW092101714A patent/TW200302748A/zh unknown
- 2003-01-28 WO PCT/IB2003/000265 patent/WO2003063823A2/en active IP Right Grant
- 2003-01-28 BR BR0307320-3A patent/BR0307320A/pt not_active IP Right Cessation
- 2003-01-28 ES ES03701640T patent/ES2277632T3/es not_active Expired - Lifetime
- 2003-01-28 JP JP2003563517A patent/JP2005518418A/ja not_active Abandoned
- 2003-01-28 AT AT03701640T patent/ATE345776T1/de not_active IP Right Cessation
- 2003-01-28 MX MXPA04007437A patent/MXPA04007437A/es unknown
- 2003-01-28 NZ NZ533986A patent/NZ533986A/xx unknown
- 2003-01-28 DE DE60309832T patent/DE60309832T2/de not_active Expired - Lifetime
- 2003-01-28 CN CNA038031213A patent/CN1625388A/zh active Pending
- 2003-01-28 CA CA002474425A patent/CA2474425A1/en not_active Abandoned
- 2003-01-28 EP EP03701640A patent/EP1469826B1/en not_active Expired - Lifetime
- 2003-01-28 KR KR10-2004-7011821A patent/KR20040083492A/ko active IP Right Grant
- 2003-01-28 RU RU2004123623/15A patent/RU2004123623A/ru not_active Application Discontinuation
- 2003-01-28 PL PL03372172A patent/PL372172A1/xx unknown
- 2003-01-29 GT GT200300017A patent/GT200300017A/es unknown
- 2003-01-30 PE PE2003000100A patent/PE20030801A1/es not_active Application Discontinuation
- 2003-01-30 AR ARP030100272A patent/AR038373A1/es unknown
- 2003-01-31 UY UY27644A patent/UY27644A1/es not_active Application Discontinuation
- 2003-02-03 PA PA20038565201A patent/PA8565201A1/es unknown
-
2004
- 2004-07-07 ZA ZA200405406A patent/ZA200405406B/en unknown
- 2004-08-31 NO NO20043646A patent/NO20043646L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1469826A2 (en) | 2004-10-27 |
| ES2277632T3 (es) | 2007-07-16 |
| DE60309832T2 (de) | 2007-10-11 |
| CA2474425A1 (en) | 2003-08-07 |
| GT200300017A (es) | 2003-09-22 |
| KR20040083492A (ko) | 2004-10-02 |
| DE60309832D1 (de) | 2007-01-04 |
| PL372172A1 (en) | 2005-07-11 |
| WO2003063823A2 (en) | 2003-08-07 |
| JP2005518418A (ja) | 2005-06-23 |
| AR038373A1 (es) | 2005-01-12 |
| ATE345776T1 (de) | 2006-12-15 |
| NZ533986A (en) | 2006-03-31 |
| EP1469826B1 (en) | 2006-11-22 |
| ZA200405406B (en) | 2005-07-07 |
| NO20043646L (no) | 2004-08-31 |
| PE20030801A1 (es) | 2003-09-19 |
| BR0307320A (pt) | 2004-12-28 |
| MXPA04007437A (es) | 2004-10-11 |
| TW200302748A (en) | 2003-08-16 |
| CN1625388A (zh) | 2005-06-08 |
| WO2003063823A3 (en) | 2003-12-04 |
| UY27644A1 (es) | 2003-09-30 |
| PA8565201A1 (es) | 2003-12-10 |
| US20030175346A1 (en) | 2003-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2004123623A (ru) | Системы осмотической доставки | |
| EP0050480B1 (en) | Long lasting multi-layered film preparation and process for its production | |
| CA1326821C (en) | Generic zero order controlled drug delivery system | |
| US8475813B2 (en) | Methods of treatment using a gastric retained gabapentin dosage | |
| EP1875910B1 (en) | Application of levo-ornidazole in preparation of anti-anaerobic bacteria infection medicine | |
| CA1261703A (en) | Verapamil dosage form | |
| RU2003138075A (ru) | Удерживаемая в желудке система регулируемой доставки лекарственного средства | |
| AU608806B2 (en) | Sustained release dosage forms | |
| CN104069502B (zh) | 复合骨架材料及其药物组合物 | |
| CA2398035A1 (en) | Timed pulsatile drug delivery systems | |
| JPS61267528A (ja) | 吸収促進剤を含有するカルシトニン経鼻剤 | |
| ATE275396T1 (de) | Aus mehreren einzeleinheiten zusammengesetztes pharmazeutisches präparat, das einen protonenpumpeninhibitor enthält | |
| RU2004134728A (ru) | Дозированные формы и композиции для осмотической доставки различных дозировок оксикодона | |
| KR101322527B1 (ko) | 잔탄 검 및 테르페노이드를 포함하는 점안제 | |
| JP2005518418A5 (ru) | ||
| KR20120056864A (ko) | 삼투 펌프 제어 방출 정제 및 이의 제조방법 | |
| MXPA04005667A (es) | Tableta farmaceutica de metformina de liberacion prolongada. | |
| EP1413295B1 (en) | Sustained release composition for oral administration of drugs | |
| WO2001080824A3 (en) | Dual mechanism timed release dosage forms for low dose drugs | |
| FI75991C (fi) | Foerfarande foer framstaellning av stabil isotonisk vaetskekomposition, vilken kan anvaendas som oegonmedicinpreparat. | |
| Lee et al. | Overview of controlled-release drug delivery | |
| EP2377522A1 (en) | Orally disintegrating tablet formulations of mirtazapine and process for preparing the same | |
| RU2002129588A (ru) | Новые препараты альфа -2,4-дисульфофенил-n-трет-бутилнитрона | |
| EP1839665A1 (en) | Intraoral disintegration type solid preparation containing povidone iodine | |
| RU2000129666A (ru) | Стабильные растворы митоксантрона |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20070316 |